A Randomized, Multicenter, Double-Blind, Placebo-Controlled Development Program to Evaluate the Efficacy and Safety of LY4268989 (MORF-057) for the Treatment of Adults With Moderately to Severely Active Ulcerative Colitis (EMERALD-3)
A Randomized, Multicenter, Double-Blind, Placebo-Controlled Development Program to Evaluate the Efficacy and Safety of LY4268989 (MORF-057) for the Treatment of Adults With Moderately to Severely Active Ulcerative Colitis (EMERALD-3)
The main purpose of this study is to evaluate the safety and effectiveness of LY4268989 when compared to placebo in adult participants with moderately to severely active ulcerative colitis (UC). The study drug will be administered orally.
The study will last up to approximately 108 weeks, excluding screening.
Inclusion Criteria:
Exclusion Criteria:
Have a current diagnosis of
Have an inherited immunodeficiency syndrome or known monogenic cause of UC-like colonic inflammation
Have had or will need bowel resection or intestinal or intra-abdominal surgery
Have evidence of toxic megacolon, intra-abdominal abscess, or stricture or stenosis within small bowel or colon that cannot be traversed by a colonoscope or that are symptomatic
Have any prior or current evidence of cancer gastrointestinal (GI) tract, or specified lesions with increased risk of GI malignancies
Have a diagnosis or history of malignant disease within 5 years prior to randomization
LillyTrials@Lilly.com1-317-615-4559
clinical_inquiry_hub@lilly.com
Phoenix, Arizona 85008, United States
602-344-5194
Lakewood, Colorado 80228, United States
Mandeville, Louisiana 70471, United States
Wyoming, Michigan 49519, United States
Las Vegas, Nevada 89128, United States
Moorestown, New Jersey 08057, United States
Greenville, North Carolina 27834, United States
Springboro, Ohio 45066, United States
Westlake, Ohio 44145, United States
Charleston, South Carolina 29425, United States
Spokane, Washington 99208, United States
Salvador, 41920-900, Brazil
Tajaí, 88301-220, Brazil
Taian, 271000, China
13375387610
Neuilly-sur-Seine, 92200, France
Belgavi, 590019, India
Mumbai, 400008, India
Hirosaki, 036-8545, Japan
Kaunas, LT-50161, Lithuania
Ciudad de Tijuana, 22105, Mexico
Guadalajara, 44650, Mexico
Mexico City, 14080, Mexico
Lisbon, 1649-035, Portugal
Santa Maria da Feira, 4520-211, Portugal
Kaohsiung City, 807, Taiwan
Kiev, 04050, Ukraine
Kyiv, 04106, Ukraine
661-388-2239
661-388-2239
719-310-6719
407-954-4016
941-727-7772
407-303-9921
208-813-6505
208-528-4256
312-695-4077
312-767-3244
217-528-7541
812-206-1702
502-888-1988
985-323-4003
314-254-3168
252-758-8181
440-250-7630
843-792-3710
731-280-0157
817-612-5575
972-265-8201
281-453-2005
817-417-9664
210-581-2812
512-878-1100
903-630-6211
590-474-1107
509-489-2600
253-272-5127
54111550120614
+541145143408
54 11 5288 6107
01121919736
+54 9 3416 18-5727
5493415329980
5493816299018
19 3252-5611
+55 41 99968-0290
+5551999624012
55 71 2108-5600
+5513997113072
5511999158070
18981838298
86-13508389768
3212108418
+420466014229
+420 222 501 720
+420 725 505 279
+ 420 606 661 523
+420 775 316 692
01 41 43 05 73
+306976062713
2810392037
06309399575
+36209650290
36309578269
0141-4039432
04842154754
8475000331
09867932836
+9720723398277
+97286745244
972-4-7772850
+97225457100
+97297471017
9728779720
39 0252774951
02 99430.3264
+390668370271
0282243263
81120023812
81120023812
81120023812
81120023812
81120023812
81120023812
81120023812
81120023812
81120023812
81120023812
81120023812
81120023812
81120023812
81120023812
81120023812
+37046345968
5510546591
+48 518 424 470
+48 724 444 299
48 91 433 29 19
48515342221
500111648
48606930022
351256379733
787-407-3333
787-7540101x5420
+421917752297
+421907798994
+421903607349
+421 905 218 417
+421 918 477 281
+27219300923
+27832844682
82422209501
82-53-620-3830
82-51-797-0220
027408112
+905325467187
+90 505 782 38 08
905326145276
+380503741659
+380979132763
+380445949200
+380937694807
380445947078
+380506381700
+380972094524
0933825853
+380997279631
+380676222307